Cellebrite DI Ltd. $CLBT Stock: Phoenix Financial Ltd. Reduces Position

Phoenix Financial Ltd. cut its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.3% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,111,006 shares of the company’s stock after selling 1,070,263 shares during the period. Phoenix Financial Ltd. owned approximately 2.05% of Cellebrite DI worth $57,553,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nine Ten Capital Management LLC grew its position in Cellebrite DI by 19.8% in the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after acquiring an additional 682,933 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after purchasing an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after purchasing an additional 365,700 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after purchasing an additional 545,334 shares in the last quarter. Finally, Weiss Asset Management LP boosted its stake in shares of Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Weiss Ratings lowered shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday. DA Davidson reiterated a “buy” rating and issued a $15.00 price objective on shares of Cellebrite DI in a report on Tuesday, September 15th. Lake Street Capital decreased their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Needham & Company LLC raised their target price on Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research note on Thursday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus price target of $14.75.

Insider Transactions at Cellebrite DI

In related news, CFO David Barter sold 12,134 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the sale, the chief financial officer directly owned 322,085 shares of the company’s stock, valued at approximately $3,610,572.85. This represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO David Gee sold 4,323 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the sale, the chief marketing officer directly owned 135,281 shares in the company, valued at approximately $1,536,792.16. This represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 57,143 shares of company stock worth $645,005 in the last quarter. Insiders own 5.70% of the company’s stock.

Key Cellebrite DI News

Here’s some of the latest news about CLBT:

• Positive Sentiment: Cellebrite reported Q3 revenue of $149.0 million, above the cited consensus estimate of $145.8 million, and EPS of $0.17. The company also reported 20% ARR growth, a 31% trailing-twelve-month free-cash-flow margin, and $26.7 million in net income. Cellebrite Q3 results
• Positive Sentiment: Needham raised its price target from $12.50 to $14.00 and maintained a Buy rating, signaling confidence in further upside. Needham analyst ratings
• Neutral Sentiment: Two executives disclosed small share sales—234 shares by the CMO and 393 by the CRO—while retaining substantial holdings, limiting the apparent significance of the transactions. CMO SEC filing CRO SEC filing

Cellebrite DI Trading Up 5.9%

CLBT stock traded up $0.64 during midday trading on Friday, hitting $11.53. 5,109,359 shares of the company’s stock were exchanged, compared to its average volume of 1,881,015. The firm has a 50 day moving average price of $11.60 and a 200-day moving average price of $13.22. Cellebrite DI Ltd. has a 12-month low of $9.58 and a 12-month high of $19.39. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of 48.04, a price-to-earnings-growth ratio of 1.67 and a beta of 1.06.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, November 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.09 by $0.08. The business had revenue of $149.02 million for the quarter, compared to analysts’ expectations of $145.83 million. Cellebrite DI had a net margin of 12.14% and a return on equity of 17.47%. On average, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.37 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.